

Product Data Sheet

IL-17A Protein, Mouse (HEK293, His-Avi)

HY-P78320
CTLA-8; IL17; IL17A; IL-17CTLA-8; interleukin 17A
Mouse
HEK293
Q62386 (A26-A158)
16171
20-28 kDa

PROPERTIES	
Biological Activity	Immobilized Mouse IL-17A, His Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Mouse IL-17RA, hFc Tag with the EC ₅₀ of 64.9ng/ml determined by ELISA.
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 $\mu g/mL$ in ddH_2O.
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	Interleukin-17A (IL-17A), also known as CTLA-8, belongs to the IL-17 cytokine family. IL-17A is expressed in memory Th17 cells and is a product of memory CD4 ⁺ T cells. IL-17A is also produced by a wide variety of immune cells, including CD8 ⁺ T cells, γδT cells, natural killer T (NKT) cells, monocytes, and neutrophils ^{[1][2][3]} .
	The mouse IL-17A shares 63.23% amino acid sequence identity with human and 87.33% identity with rat.
	IL-17A plays a critical role in host defense mechanisms against many bacterial and fungal pathogens as well as allergic and
	autoimmune responses. IL-17A induces the production of antimicrobial peptides (defensins and S100 proteins), cytokines
	(IL-6, G-CSF, and GM-CSF), chemokines (CXCL1, CXCL5, IL-8, CCL2, and CCL7), and matrix metalloproteinases (MMP1, MMP3,
	and MMP13). IL-17A is detrimental in viral infection through promoting neutrophilic inflammation. IL-17A is a homodimeric
	cytokine and shares similar biological activities with IL-17F. IL-17A binds to IL-17RA with high affinity, and IL-17RA is
	required for the biological activity of IL-17A. In tumorigenesis, IL-17A recruits myeloid derived suppressor cells (MDSCs) to
	dampen anti-tumor immunity. IL-17A also enhances tumor growth in vivo through the induction of IL-6 $^{[1][2]}$.
	IL-17A can be used for the research of autoimmune diseases, infection and cancer ^{[1][4]} .

REFERENCES

[1]. Chen K, et al. Interluekin-17A (IL17A). Gene. 2017 May 30;614:8-14.

[2]. Iwakura Y, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008 Dec;226:57-79.

[3]. Cua DJ, et al. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010 Jul;10(7):479-89.

[4]. Wright JF, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008 Aug 15;181(4):2799-805.

[5]. Pelidou SH, et al. Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol. 2000 May;163(1):165-72.

[6]. Liu Y, et al. IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol. 2011 Mar 1;186(5):3197-205.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA